Navigation Links
Advocates for Youth Applauds Court Ruling on EC Age Restriction
Date:3/23/2009

ration sought to unduly influence the agency during the Plan B application review process. Testimony also indicated that officials involved in the decision-making process were concerned about losing their jobs if they did not follow the Administration's political directives."

Advocates for Youth is a national organization that promotes programs and advocates for policies that help young people make informed and responsible decisions about their reproductive and sexual health.


'/>"/>
SOURCE Advocates for Youth
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. House Bill to Improve Accuracy of Medicare Reimbursement Introduced: Members of Congress Seek to Stem Growing Healthcare Coverage Shortfalls, Community Oncology Alliance Advocates for Swift Passage of Bill
2. Global War on Drugs Takes Devastating Toll on Human Lives, Advocates Say
3. Illinois Advocates Take on Health Insurance Industry
4. Healthcare Liaison Graduates Nations First Credentialed Private Healthcare Advocates - Graduates are Pioneers in Emerging Profession
5. Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development
6. Parents and Advocates Label Todays Vaccine Court Rulings Insincere and Politically Driven, Says National Autism Association
7. Consumer Advocates Call on Legislature to Support Governors Ban on Pharmaceutical Gifts to Doctors
8. Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association
9. Allstate and Advocates for Highway and Auto Safety Unveil Public Policy Fellowship Program
10. Advocates Call on Legislature to Stop Proposed Rx Cuts to the Elderly and Poor
11. Advocates Launches Amplify - a New Youth Activist Website
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 1Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 2Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 3CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 1CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 2CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 3CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 4CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 5A Little Cash Buys a Lot of Calories at the Corner Store 59282 1A Little Cash Buys a Lot of Calories at the Corner Store 59282 2